CDEK
← All drugs Report issue

utomilumab

mAbexperimental

CD137, a member of the tumor necrosis factor (TNF) receptor family, is a type 1 transmembrane protein, expressed on surfaces of leukocytes and non-immune cells. Its alternative names are tumor necrosis factor receptor superfamily member 9 (TNFRSF9), 4-1BB, and induced by lymphocyte activation (ILA). It is of interest to immunologists as a co-stimulatory immune checkpoint molecule, and as a potential target in cancer immunotherapy. — Wikipedia

Clinical trial activity

17 trials · 22 clinical orgs · 0 marketing orgs

Phase 1
11
Phase 2
8
Phase 3
2
Phase 4
0

Earliest trial started Jun 21, 2011 (NCT01307267)

Timeline

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2015

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2016

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • pf-05082566
  • pf-05082566
  • utomilumab
  • utomilumab

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05059522Phase 3Sep 29, 2021Pfizer
NCT03971409Phase 2Jul 1, 2019Array BioPharma, Breast Cancer Research Foundation, Hoosier Cancer Research Network, Johns Hopkins University, Pfizer, Translational Breast Cancer Research Consortium, University of California, San Francisco
NCT03704298Phase 1/Phase 2 (Phase 2)Nov 20, 2018Gilead Sciences, Pfizer
NCT03636503Phase 1Sep 30, 2018Harvard University, Pfizer
NCT03318900Phase 1Jul 16, 2018immatics Biotechnologies GmbH, Markel/Friedman Accelerator Fund, Pfizer, University of Texas at Houston
NCT03414658Phase 2Jun 21, 2018Breast Cancer Research Foundation, Harvard University, Johns Hopkins University, Pfizer
NCT03440567Phase 1Jun 8, 2018City of Hope National Medical Center, National Cancer Institute (NCI)
NCT03258008Phase 2Apr 4, 2018ISA Pharmaceuticals, Pfizer, University of Texas at Houston
NCT03290937Phase 1Dec 27, 2017Pfizer, University of Texas at Houston
NCT03364348Phase 1Oct 30, 2017National Cancer Institute (NCI), Stanford University
NCT03217747Phase 1/Phase 2 (Phase 2)Aug 2, 2017Pfizer, University of Texas at Houston
NCT02951156Phase 3Dec 16, 2016Merck Serono, Pfizer
NCT02554812Phase 2Nov 1, 2015Pfizer
NCT02444793Phase 1May 26, 2015Georgetown University, Kyowa Hakko Kirin, Pfizer, University of California, San Diego, University of Rochester
NCT02315066Phase 1Apr 23, 2015Pfizer
NCT02179918Phase 1Aug 19, 2014Merck, Pfizer
NCT01307267Phase 1Jun 21, 2011Pfizer
Showing 17 of 17 trials
Page 1 / 1

Organizations

Research & Development (22)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
PfizerFor profit15732011
University of Texas at HoustonAcademic/Hospital4422017
Breast Cancer Research FoundationAcademic/Hospital2012018
Harvard UniversityAcademic/Hospital2222018
Johns Hopkins UniversityAcademic/Hospital2012018
National Cancer Institute (NCI)Government2012017
Array BioPharmaFor profit1012019
City of Hope National Medical CenterAcademic/Hospital1112018
Georgetown UniversityAcademic/Hospital1012015
Gilead SciencesFor profit1112018
Hoosier Cancer Research NetworkAcademic/Hospital1012019
immatics Biotechnologies GmbHFor profit1012018
ISA PharmaceuticalsFor profit1012018
Kyowa Hakko KirinFor profit1012015
Markel/Friedman Accelerator FundAcademic/Hospital1012018
MerckFor profit1012014
Merck SeronoFor profit1012016
Stanford UniversityAcademic/Hospital1112017
Translational Breast Cancer Research ConsortiumAcademic/Hospital1012019
University of California, San DiegoAcademic/Hospital1012015
22 organizations
Page 1 / 2